ranbaxy in norway: The Norwegian Appeals Court ruled that Ranbaxy Laboratories Ltd's generic version of Lipitor did not infringe Pfizer Inc's patents. Ranbaxy says they will now be able to market their products in Norway. Pfizer markets its cholesterol-lowering drug Atorvastatin as Lipitor. The court ruled that three Pfizer patents covering intermediate compounds used to make Atorvastatin, the active ingredients in Liptor, would not be infringed by the sale of a Ranbaxy's generic product in Norway. The two companies have been involved in a patent battle in various markets across the globe.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.